company background image
ANVS logo

Annovis Bio NYSE:ANVS Stock Report

Last Price

US$5.01

Market Cap

US$69.1m

7D

-2.0%

1Y

-67.4%

Updated

24 Dec, 2024

Data

Company Financials +

My Notes

Capture your thoughts, links and company narrative

Annovis Bio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Annovis Bio
Historical stock prices
Current Share PriceUS$5.01
52 Week HighUS$22.49
52 Week LowUS$4.21
Beta1.59
1 Month Change-24.66%
3 Month Change-37.06%
1 Year Change-67.36%
3 Year Change-73.48%
5 Year Changen/a
Change since IPO-47.76%

Recent News & Updates

We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate

Dec 06
We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate

Annovis Bio To Continue Alzheimer's Disease Clinical Trials

Oct 17

Recent updates

We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate

Dec 06
We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate

Annovis Bio To Continue Alzheimer's Disease Clinical Trials

Oct 17

Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom

Sep 27

Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints

Jul 08

Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease

Jun 30

Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question

May 02

Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects

Feb 12

Annovis And Alzheimer's Disease: The Best-Laid Plans

Jan 30

Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials

Jan 20

Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts

Oct 16

Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely

Sep 08
Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely

Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum

Jun 28

Annovis wins EU nod to expand late-stage trial for Parkinson's candidate

Feb 08

We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Jan 28
We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug

Jan 25

Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look

Oct 06

We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely

Sep 15
We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely

Annovis Bio announces publication of three U.S. patents covering lead asset

Sep 13

Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate

Aug 24

Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate

Jul 07

Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans

May 14
Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans

We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Feb 10
We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation

Apr 16
Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation

Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?

Feb 23
Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?

We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth

Jan 01
We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth

Shareholder Returns

ANVSUS BiotechsUS Market
7D-2.0%-3.3%-0.4%
1Y-67.4%-2.7%24.8%

Return vs Industry: ANVS underperformed the US Biotechs industry which returned -1.9% over the past year.

Return vs Market: ANVS underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is ANVS's price volatile compared to industry and market?
ANVS volatility
ANVS Average Weekly Movement11.2%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: ANVS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ANVS's weekly volatility has decreased from 22% to 11% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200811Maria Maccecchiniwww.annovisbio.com

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company’s lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer’s disease (AD), Parkinson’s disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia.

Annovis Bio, Inc. Fundamentals Summary

How do Annovis Bio's earnings and revenue compare to its market cap?
ANVS fundamental statistics
Market capUS$69.12m
Earnings (TTM)-US$40.94m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ANVS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$40.94m
Earnings-US$40.94m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.97
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ANVS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 14:13
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Annovis Bio, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tyler BussianBrookline Capital Markets
Sumant Satchidanand KulkarniCanaccord Genuity
Jason KolbertD. Boral Capital LLC.